CTOs on the Move

Arcutis

www.arcutis.com

 
Arcutis was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team`s ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.arcutis.com
  • 3027 Townsgate Road Suite 300
    Westlake Village, CA USA 91361
  • Phone: 805.418.5006

Executives

Name Title Contact Details
Rajvir Madan
Chief Digital and Information Officer Profile

Funding

Arcutis raised $94.5M on 10/22/2019

Similar Companies

Cellnetix

Cellnetix is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Solutions

Advanced Solutions designs and manufactures biofabrication systems for next-generation drug discovery, personalized medicine, and regenerative therapeutics.

Antibe Therapeutics

Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.

Cellular Genomics

Cellular Genomics, Inc. is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.